Comparative Pharmacology
Head-to-head clinical analysis: IFOSFAMIDE versus MUSTARGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IFOSFAMIDE versus MUSTARGEN.
IFOSFAMIDE vs MUSTARGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prodrug activated by cytochrome P450 to cytotoxic metabolites (4-hydroxyifosfamide, acrolein, and ifosforamide mustard) that alkylate DNA by cross-linking guanine bases, inhibiting DNA replication and transcription.
MUSTARGEN (mechlorethamine HCl) is a nitrogen mustard alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
1.2 g/m² IV over 2 hours daily for 5 consecutive days every 3 weeks, or 5 g/m² IV as a 24-hour continuous infusion every 3 weeks. Administer with mesna and vigorous hydration.
IV: 0.4 mg/kg or 12 mg/m² BSA as a single dose or divided into 0.1 mg/kg/day for 4 days.
None Documented
None Documented
Clinical Note
moderateIfosfamide + Digoxin
"Ifosfamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateIfosfamide + Digitoxin
"Ifosfamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateIfosfamide + Deslanoside
"Ifosfamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateIfosfamide + Acetyldigitoxin
"Ifosfamide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 4-7 hours for parent drug; active metabolite 4-desulfonate has half-life ~12-15 hours. Clinical context: Prolonged with renal impairment.
Terminal half-life: 30-60 minutes (rapidly inactivated); clinical context: very short due to rapid hydrolysis and alkylation, necessitating rapid administration after reconstitution.
Primarily renal: 50-60% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Renal: 50% as unchanged drug and metabolites; fecal: minor (<10%); biliary: minimal.
Category D/X
Category C
Alkylating Agent
Alkylating Agent